Aquestive Therapeutics, Inc. (AQST) vs Evolus, Inc. (EOLS)

Aquestive Therapeutics, Inc. and Evolus, Inc. are both Drug Manufacturers Specialty & Generic companies. Aquestive Therapeutics, Inc. is the larger, with a market value of $605.0M against $519.2M — 1.2× the size. Aquestive Therapeutics, Inc. grew revenue faster over the last twelve months: 22.6% against 13.9%. Evolus, Inc. has the higher net margin (−10.9% vs −144.6%) and the lower return on invested capital (−14.5% vs 0.00%). Across the 17 metrics below, Evolus, Inc. leads on 13 and Aquestive Therapeutics, Inc. on 4.

Valuation

Metric AQST EOLS Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 10.82 1.66 2.25
P/B n/m n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 9.93 2.02 2.56
Earnings yield (13.89%) (6.52%) (2.99%)
Free cash flow yield (7.85%) (4.17%) 0.00%

Profitability

Metric AQST EOLS Drug Manufacturers Specialty & Generic median
Gross margin 67.04% 66.74% 53.94%
Operating margin (97.52%) (5.90%) 0.00%
Net margin (144.63%) (10.85%) 0.00%
Free cash flow margin (84.95%) (6.92%) 0.00%
Return on equity 121.12% 138.57% (0.40%)
Return on assets (69.29%) (14.40%) (3.32%)
Return on invested capital 0.00% (14.47%) 0.00%

Growth

Metric AQST EOLS Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 22.56% 13.87% 10.01%
EPS growth (last fiscal year) (52.94%) 1.23% —
Revenue growth, 5-year CAGR (0.58%) 39.36% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AQST EOLS Drug Manufacturers Specialty & Generic median
Debt to equity (0.90) (5.07) 0.05
Current ratio 7.19 1.70 2.31
Net debt to EBITDA 1.57 (4.08) 0.85

Dividend

Metric AQST EOLS Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric AQST EOLS Drug Manufacturers Specialty & Generic median
Market cap 604.97m 519.16m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack